Sumanta K. Pal, MD, FASCO(@montypal) 's Twitter Profileg
Sumanta K. Pal, MD, FASCO

@montypal

@cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail [email protected].

ID:24660850

linkhttp://bit.ly/2doQCBh calendar_today16-03-2009 06:46:19

23,8K Tweets

18,8K Followers

3,8K Following

Follow People
Dr Amol Akhade(@SuyogCancer) 's Twitter Profile Photo

Tweeting ' live ' from conference, virtually or in person , is important. For self ( notes to myself ) and to many of the colleagues who can not attend in person or virtually , especially from LMICs .

Sharing is caring 🙂 OncoAlert ASCO

account_circle
Jun Gong(@jgong15) 's Twitter Profile Photo

Updated 2-yr analysis of GALAXY observational cohort in StI-IV shows sustained predictive power or ctDNA+ for inferior DFS, sustained ctDNA clearance w/superior DFS, 98% of those w/transient clearance became ctDNA+ by 18 mos post surgery OncoAlert

Updated 2-yr analysis of GALAXY observational #ctDNA cohort in StI-IV #CRC shows sustained predictive power or ctDNA+ for inferior DFS, sustained ctDNA clearance w/superior DFS, 98% of those w/transient clearance became ctDNA+ by 18 mos post surgery #GI24 @OncoAlert
account_circle
Sabine D. Brookman-May(@brookmans76) 's Twitter Profile Photo

Full FDA approval for for the treatment of pts with locally advanced/metastatic FGFR+ following prior systemic therapy, based on data from THOR/Cohort 1): 36% risk reduction in death in pts with prior PD1/PDL1 inhibition vs chemo J&J Innovative Medicine

Full FDA approval for #Erdafitinib for the treatment of pts with locally advanced/metastatic FGFR+ #UrothelialCarcinoma following prior systemic therapy, based on data from THOR/Cohort 1): 36% risk reduction in death in pts with prior PD1/PDL1 inhibition vs chemo @JNJInnovMed
account_circle
Jonathan Friedberg(@DrJFriedberg) 's Twitter Profile Photo

An important paper on the importance of Grade 1-2 AEs underscoring the critical importance of monitoring and reporting these events in trials, ideally with PROs tools.
Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

account_circle
Jun Gong(@jgong15) 's Twitter Profile Photo

Rand PhII multicenter RAISE trial of adjuvant therapy (RT) 50 Gy/25 fractions IMRT w/R0 resected w/resection margin <1 cm ➡️ 2-yr RFS 78.7% w/adj RT vs 58.4% control (most recurrences were local at resection margin if occurred) OncoAlert

Rand PhII multicenter RAISE trial of adjuvant #radiation therapy (RT) 50 Gy/25 fractions IMRT w/R0 resected #HCC w/resection margin <1 cm ➡️ 2-yr RFS 78.7% w/adj RT vs 58.4% control (most recurrences were local at resection margin if occurred) #GI24 @OncoAlert
account_circle
Oncology Brothers(@OncBrothers) 's Twitter Profile Photo

now FDA Oncology approved for locally advanced or mUC w/ FGFR3 after at least 1L of prior systemic Rx (THOR study).

- mOS 12.1mos w/ Erdafitinb vs 7.8mos w/ chemo (HR: 0.64)
- ORR 35.3% vs 8.5%
- AEs: ⬆️Phos, diarrhea, & dry eyes

#Erdafitinib now @FDAOncology approved for locally advanced or mUC w/ FGFR3 after at least 1L of prior systemic Rx (THOR study). - mOS 12.1mos w/ Erdafitinb vs 7.8mos w/ chemo (HR: 0.64) - ORR 35.3% vs 8.5% - AEs: ⬆️Phos, diarrhea, & dry eyes #OncTwitter #gusm #BladderCancer
account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

JUST IN: U.S. FDA approved erdafitinib for metastatic urothelial carcinoma (mUC) w/FGFR3 alterations, post 1 line TX. Approval based on THOR trial in NEJM; led by ylt GustaveRoussy & MD Anderson Cancer Center presented ASCO

nejm.org/doi/full/10.10…

Link:…

JUST IN: @US_FDA approved erdafitinib for metastatic urothelial carcinoma (mUC) w/FGFR3 alterations, post 1 line TX. Approval based on THOR trial in @NEJM; led by @y_loriot @GustaveRoussy & #siefkerRadtke @MDAndersonNews presented #ASCO23 @ASCO nejm.org/doi/full/10.10… Link:…
account_circle
Cure GI Cancers(@RueschCenter) 's Twitter Profile Photo

Dr. Marcus Noel (Marcus S. Noel) and Dr. Laleh G. Melstrom (@laleh_melstrom) are chairing the Rapid Oral Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract at . Georgetown Lombardi City of Hope Surgery ASCO

Dr. Marcus Noel (@mnoel3232) and Dr. Laleh G. Melstrom (@laleh_melstrom) are chairing the Rapid Oral Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract at #GI24. @LombardiCancer @CityofHopeSurg @ASCO
account_circle
Jun Gong(@jgong15) 's Twitter Profile Photo

Milind Javle novel inh tinengotinib with ORR 40% in CCA pts with acquired resistance to prior FGFR inh

PhIII ongoing for FGFR-altered chemo and FGFR inh advanced CCA

OncoAlert

@JavleMilind novel #FGFR inh tinengotinib with ORR 40% in CCA pts with acquired resistance to prior FGFR inh PhIII ongoing for FGFR-altered chemo and FGFR inh advanced CCA #GI24 @OncoAlert
account_circle